MGXMetagenomi Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Metagenomi Therapeutics, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MGXEsta | $43M#9 | — | 0.4x#1 | 1.7x#2 | -51.8%#6 | -12.6%#6 | -380.9%#1 | -78.1%#6 | — | — | -37.3%#5 | — |
| IMA | $58M#1 | — | 0.4x#2 | 71.9x#3 | -77.1%#7 | -24.0%#8 | -6056.4%#4 | -31.9%#3 | — | — | -39.9%#6 | — |
| INMB | $57M#2 | — | 2.8x#7 | 1140.7x#6 | 257.1%#1 | -9.5%#5 | -94766.0%#7 | -225.9%#8 | -607.3%#4 | — | 3.3%#3 | — |
| BKHAU | $53M#3 | — | — | — | — | -30.6%#9 | — | — | — | — | 133.8%#1 | 96.2%#2 |
| TVGN | $50M#4 | — | — | — | — | -91.4%#13 | — | — | — | — | -81.8%#13 | — |
| TIL | $49M#6 | — | 0.5x#3 | — | -100.0%#8 | 3.7%#4 | — | -66.5%#4 | — | — | -68.4%#10 | — |
| BKHA | $49M#7 | — | — | — | — | -30.6%#9 | — | — | — | — | 126.3%#2 | 104.1%#1 |
| SCLX | $45M#8 | — | — | 1.5x#1 | -46.5%#5 | -413.8%#15 | -1143.7%#2 | — | — | 4#1 | -71.9%#11 | — |
| ATYR | $37M#10 | — | 0.8x#5 | 197.3x#5 | -19.1%#3 | -15.8%#7 | -40856.3%#6 | -151.9%#7 | -202.0%#2 | — | -64.3%#9 | — |
| ALGS | — | — | — | — | -39.5%#4 | 81.6%#2 | -4024.9%#3 | -75.9%#5 | — | — | -43.4%#8 | — |
| QNCX | $28M#11 | 0.2x#2 | — | — | — | -47.8%#11 | — | — | — | — | -91.4%#15 | — |
| ESLA | $28M#13 | — | — | — | — | — | — | — | — | — | -41.4%#7 | — |
| CVM | $26M#14 | — | 2.4x#6 | 99.9x#4 | 65.5%#2 | 5.6%#3 | -9396.5%#5 | -231.9%#9 | — | — | -84.2%#14 | — |
| GRMLW | $28M#12 | — | 0.5x#4 | — | — | -71.6%#12 | — | -18.2%#2 | -14.6%#1 | — | -33.1%#4 | — |
| JSPR | $19M#15 | — | 13.7x#9 | — | — | 100.0%#1 | — | -0.0%#1 | — | — | -76.1%#12 | — |
| PHGE | $49M#5 | 0.1x#1 | 4.5x#8 | — | — | -104.2%#14 | — | -333.2%#10 | -377.8%#3 | — | -97.9%#16 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice